PROTACs usually occupy physicochemical space outside the one defined by classical drug-like molecules, which often presents considerable challenges in their optimization and development for oral administration. We have previously reported phenyl glutarimide (PG)-based BET PROTAC SJ995973, with improved overall in vitro degradation and antiproliferative activities compared to its direct thalidomide-based analogue dBET1, but similarly poor in vivo pharmacokinetic profile. Here we describe optimization efforts that led to the discovery of an orally bioavailable PG-PROTAC SJ44236, and results of a comprehensive in vitro/vivo comparative study with direct analogues containing alternative CRBN warheads.
[doi:10.25345/C5Z31P129]
[dataset license: CC0 1.0 Universal (CC0 1.0)]
Keywords: Targeted protein degradation, PROTACs ; DatasetType:Proteomics
|
Principal Investigators: (in alphabetical order) |
Zoran Rankovic, The Institute of Cancer Research, United Kingdom |
| Submitting User: | msteger |
| Number of Files: | |
| Total Size: | |
| Spectra: | |
| Subscribers: | |
| Owner | Reanalyses | |
|---|---|---|
| Experimental Design | ||
|
Conditions:
|
||
|
Biological Replicates:
|
||
|
Technical Replicates:
|
||
| Identification Results | ||
|
Proteins (Human, Remapped):
|
||
|
Proteins (Reported):
|
||
|
Peptides:
|
||
|
Variant Peptides:
|
||
|
PSMs:
|
||
| Quantification Results | ||
|
Differential Proteins:
|
||
|
Quantified Proteins:
|
||
| Browse Dataset Files | |
|
FTP Download Link (click to copy):
|